$581 Million is the total value of BVF INC/IL's 26 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $136,491,000 | +0.7% | 3,153,665 | -12.9% | 23.48% | -10.7% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $93,568,000 | +79.0% | 7,896,061 | +50.3% | 16.10% | +58.7% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $60,456,000 | +19.6% | 9,719,589 | -12.7% | 10.40% | +6.1% |
| EXELIXIS INCnote 4.250% 08/15/2019 | $48,016,000 | +21.8% | 40,735,000 | 0.0% | 8.26% | +8.0% | ||
| RIGL | RIGEL PHARMACEUTICALS INC | $34,836,000 | +7.2% | 9,730,697 | 0.0% | 5.99% | -5.0% | |
| TRGT | TARGACEPT INC | $32,772,000 | +24.4% | 6,171,669 | 0.0% | 5.64% | +10.3% | |
| CCXI | Buy | CHEMOCENTRYX INC | $29,900,000 | -57.9% | 5,377,616 | +7.0% | 5.14% | -62.7% |
| ONTY | Buy | ONCOTHYREON INC | $18,278,000 | +44.8% | 8,872,778 | +9.6% | 3.14% | +28.4% |
| EXEL | EXELIXIS INC | $14,563,000 | +28.2% | 2,502,256 | 0.0% | 2.51% | +13.7% | |
| ARRAY BIOPHARMA INCnote 3.000% 06/01/2020 | $13,680,000 | +19.8% | 12,000,000 | 0.0% | 2.35% | +6.2% | ||
| CYTK | New | CYTOKINETICS INC | $13,046,000 | – | 1,718,905 | +100.0% | 2.24% | – |
| RGDO | New | REGADO BIOSCIENCES INC | $11,099,000 | – | 1,659,091 | +100.0% | 1.91% | – |
| QLTI | QLT INC | $10,974,000 | +5.5% | 2,370,263 | 0.0% | 1.89% | -6.5% | |
| AVNR | Buy | AVANIR PHARMACEUTICALS INCcl a new | $10,329,000 | +123.2% | 2,436,053 | +142.1% | 1.78% | +97.9% |
| RCPT | RECEPTOS INC | $8,310,000 | +30.6% | 320,000 | 0.0% | 1.43% | +15.8% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $8,262,000 | – | 545,372 | +100.0% | 1.42% | – |
| ARQL | Buy | ARQULE INC | $6,839,000 | +12.0% | 2,935,187 | +11.5% | 1.18% | -0.7% |
| PTIE | PAIN THERAPEUTICS INC | $6,412,000 | +23.1% | 2,357,327 | 0.0% | 1.10% | +9.1% | |
| OMED | New | ONCOMED PHARMACEUTICALS INC | $5,998,000 | – | 391,800 | +100.0% | 1.03% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $5,508,000 | – | 196,996 | +100.0% | 0.95% | – |
| PTN | PALATIN TECHNOLOGIES INC | $3,510,000 | +12.5% | 5,200,000 | 0.0% | 0.60% | -0.2% | |
| SPHS | New | SOPHIRIS BIO INC | $2,808,000 | – | 600,000 | +100.0% | 0.48% | – |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $2,250,000 | – | 559,624 | +100.0% | 0.39% | – |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $2,204,000 | -15.7% | 233,689 | -12.3% | 0.38% | -25.2% |
| GNVC | GENVEC INC | $617,000 | +242.8% | 486,100 | 0.0% | 0.11% | +202.9% | |
| TSPT | TRANSCEPT PHARMACEUTICALS INC | $477,000 | +5.3% | 150,000 | 0.0% | 0.08% | -6.8% | |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -151,406 | -100.0% | -0.18% | – |
| ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -4,477,000 | -100.0% | -0.40% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -153,500 | -100.0% | -0.53% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -305,786 | -100.0% | -1.46% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -1,718,905 | -100.0% | -3.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.